| 2024-05-09 | -78.1% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2024-05-09 | -78.1% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2026-03-09 | +53.1% | earnings | Zacks | MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates |
| 2026-03-09 | +53.1% | earnings | Associated Press Finance | MacroGenics: Q4 Earnings Snapshot |
| 2026-03-09 | +53.1% | news | GlobeNewswire | MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures |
| 2026-03-09 | +53.1% | earnings | Seeking Alpha | MacroGenics GAAP EPS of -$1.18 beats by $0.03, revenue of $149.5M beats by $13.38M |
| 2026-03-09 | +53.1% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2026-03-09 | +53.1% | earnings | Yahoo Finance | MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-03-09 | +53.1% | news | GlobeNewswire | MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - GlobeNewswire |
| 2026-03-09 | +53.1% | earnings | Investing.com | MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com |
| 2026-03-09 | +53.1% | news | Stock Titan | Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan |
| 2024-04-03 | +34.7% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2024-05-13 | +34.0% | analyst | Seeking Alpha | MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade) |
| 2024-07-30 | -32.4% | legal | SEC EDGAR | MGNX 8-K: 8.01 (SEC Filing) |
| 2023-08-09 | +27.2% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2023-02-14 | -24.4% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2021-09-16 | -24.2% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2024-07-31 | -24.0% | analyst | Seeking Alpha | MacroGenics crashes as trial update leads to downgrades |
| 2022-11-03 | +21.7% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2023-11-06 | +19.4% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2024-03-07 | -19.2% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2022-05-03 | -18.7% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2022-08-08 | +16.7% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2025-12-17 | +16.6% | news | StocksToTrade | Analyzing MacroGenics Stock: To Buy Or Wait? - StocksToTrade |
| 2024-11-06 | +15.0% | earnings | Seeking Alpha | MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript |
| 2024-11-06 | +15.0% | news | Stock Titan | MacroGenics (MGNX) to Present at Guggenheim and Stifel Healthcare Conferences - Stock Titan |
| 2025-06-11 | -13.0% | news | Seeking Alpha | MacroGenics: Working On That Road To Recovery |
| 2024-10-30 | +11.8% | executive | Seeking Alpha | MacroGenics says CEO Scott Koenig to step down |
| 2024-10-30 | +11.8% | legal | SEC EDGAR | MGNX 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-03-27 | -11.2% | news | Stock Titan | Vanguard reports 0 shares in MacroGenics (NASDAQ: MGNX) - Stock Titan |
| 2022-05-24 | -10.0% | legal | SEC EDGAR | MGNX 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-08-13 | +9.9% | executive | Seeking Alpha | MacroGenics appoints new CEO |
| 2025-08-13 | +9.9% | legal | SEC EDGAR | MGNX 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-01-30 | -9.5% | news | Seeking Alpha | Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication |
| 2024-11-05 | +9.5% | earnings | Seeking Alpha | MacroGenics GAAP EPS of $0.90 beats by $0.81, revenue of $110.7M beats by $23.12M |
| 2024-11-05 | +9.5% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2025-10-22 | -9.5% | news | simplywall.st | MacroGenics, Inc. (NASDAQ:MGNX) institutional owners may be pleased with recent gains after 49% loss over the past year - simplywall.st |
| 2024-09-16 | -9.2% | legal | SEC EDGAR | MGNX 8-K: 8.01 (SEC Filing) |
| 2025-09-05 | -9.2% | M&A | Seeking Alpha | MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets |
| 2025-09-05 | -9.2% | M&A | Seeking Alpha | MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets (NASDAQ:MGNX) - Seeking Alpha |
| 2026-04-22 | -9.0% | news | Stock Titan | MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan |
| 2023-01-05 | -8.4% | legal | SEC EDGAR | MGNX 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-04-29 | -8.3% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2021-04-29 | -8.3% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2025-03-21 | -8.2% | news | Intellectia AI | MGNX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2026-02-24 | +8.1% | legal | Seeking Alpha | MacroGenics drops after FDA partial clinical hold on lead program |
| 2026-02-24 | +8.1% | legal | SEC EDGAR | MGNX 8-K: 8.01 (SEC Filing) |
| 2026-02-24 | +8.1% | legal | Seeking Alpha | MacroGenics drops after FDA partial clinical hold on lead program - Seeking Alpha |
| 2026-03-12 | -8.1% | news | Seeking Alpha | MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript |
| 2025-03-20 | -7.9% | earnings | Seeking Alpha | MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript |
| 2025-03-20 | -7.9% | earnings | Seeking Alpha | MacroGenics GAAP EPS of -$1.07 beats by $0.06, revenue of $149.96M misses by $14.82M |
| 2025-03-20 | -7.9% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2022-10-17 | +7.6% | legal | SEC EDGAR | MGNX 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-03-17 | -7.3% | news | Investing.com | MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com |
| 2022-02-24 | -7.3% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2022-09-13 | -7.3% | analyst | TradingView | MGNX Forecast — Price Target — Prediction for 2027 - TradingView |
| 2024-05-16 | -7.3% | news | GlobeNewswire | MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman - GlobeNewswire |
| 2023-03-15 | +7.3% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | -7.1% | legal | Zacks | SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay |
| 2026-04-23 | -7.1% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | MacroGenics (MGNX) Stock Research | Q4 2025: EPS Beats Forecasts - ROIC - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-11-12 | +6.9% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2021-09-27 | +6.8% | legal | SEC EDGAR | MGNX 8-K: 5.02 (SEC Filing) |
| 2021-09-08 | +6.2% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2021-06-16 | +6.0% | legal | SEC EDGAR | MGNX 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-08-06 | -5.8% | earnings | Seeking Alpha | MacroGenics GAAP EPS of -$0.89 misses by $0.30, revenue of $10.79M misses by $10.14M |
| 2024-08-06 | -5.8% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2021-07-29 | -5.4% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2023-09-10 | +5.2% | news | Seeking Alpha | MacroGenics' Undervalued Potential In Oncology Therapeutics (NASDAQ:MGNX) - Seeking Alpha |
| 2022-08-13 | -5.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for MacroGenics (MGNX) - Zacks Investment Research |
| 2026-01-06 | +5.0% | earnings | simplywall.st | There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st |
| 2026-03-07 | +5.0% | legal | Seeking Alpha | Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant |
| 2024-08-10 | -4.9% | news | Seeking Alpha | MacroGenics Faces Uncertainty After Vobra Duo Setback |
| 2023-03-16 | +4.7% | earnings | Seeking Alpha | MacroGenics stock climbs ~10% as FY22 revenue rises beating estimates - Seeking Alpha |
| 2026-02-26 | +4.7% | earnings | Zacks | BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates |
| 2026-02-26 | +4.7% | news | Stock Titan | Cancer drug developer MacroGenics lines up March investor talks - Stock Titan |
| 2022-01-07 | -4.7% | legal | SEC EDGAR | MGNX 8-K: 5.02 (SEC Filing) |
| 2025-08-14 | -4.6% | earnings | Seeking Alpha | MacroGenics GAAP EPS of -$0.57 misses by $0.10, revenue of $22.24M misses by $5.82M |
| 2025-08-14 | -4.6% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2025-11-17 | +4.4% | news | Investing.com | MacroGenics’s SWOT analysis: biotech stock faces pivotal moment amid pipeline shifts - Investing.com |
| 2025-06-10 | +4.0% | M&A | Seeking Alpha | MacroGenics signs financial deal with Sagard for retifanlimab |
| 2025-06-10 | +4.0% | legal | SEC EDGAR | MGNX 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-02-26 | -4.0% | legal | SEC EDGAR | MGNX 8-K: 5.02 (SEC Filing) |
| 2026-04-09 | +3.8% | legal | Seeking Alpha | MacroGenics gains removal of FDA partial hold on lead program |
| 2026-04-09 | +3.8% | legal | Seeking Alpha | MacroGenics gains removal of FDA partial hold on lead program - Seeking Alpha |
| 2023-03-24 | -3.7% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2025-11-13 | +3.7% | earnings | Seeking Alpha | MacroGenics GAAP EPS of $0.27 beats by $0.47, revenue of $72.84M beats by $38.95M |
| 2025-05-12 | +3.7% | earnings | Seeking Alpha | MacroGenics Q1 2025 Earnings Preview |
| 2026-03-02 | -3.7% | legal | SEC EDGAR | MGNX 8-K: 8.01 (SEC Filing) |
| 2024-11-04 | -3.6% | earnings | Seeking Alpha | MacroGenics Q3 2024 Earnings Preview |
| 2026-04-15 | -3.3% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | MacroGenics (MGNX) Stock Take Profit (Momentum Building) 2026-04-15 - Global Trading Community - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2025-05-13 | -3.3% | earnings | Seeking Alpha | MacroGenics GAAP EPS of -$0.65 beats by $0.07, revenue of $13.19M beats by $3.6M |
| 2025-05-13 | -3.3% | legal | SEC EDGAR | MGNX 8-K: 2.02 (SEC Filing) |
| 2024-10-29 | -3.3% | news | Stock Titan | MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - Stock Titan |
| 2022-12-16 | -3.2% | legal | SEC EDGAR | MGNX 8-K: 1.01 (SEC Filing) |
| 2026-04-16 | -3.2% | news | UBND thành phố Hải Phòng | MacroGenics (MGNX) Stock: Stabilizing? (Smart Money Outflows) 2026-04-16 - High Volume Stocks - UBND thành phố Hải Phòng |
| 2021-11-02 | +3.1% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2024-10-22 | +3.0% | M&A | Seeking Alpha | TerSera Therapeutics to acquire global rights to MARGENZA |
| 2022-11-18 | -3.0% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2024-08-05 | -2.9% | news | GlobeNewswire | MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein - GlobeNewswire |
| 2024-11-07 | +2.6% | analyst | Seeking Alpha | MacroGenics downgraded to market perform by JMP, price target removed |
| 2022-07-10 | +2.6% | analyst | eToro | MGNX Stock Price | Analyst Target 5.00 & Consensus - eToro |
| 2022-07-08 | +2.1% | legal | SEC EDGAR | MGNX 8-K: 8.01 and (SEC Filing) |
| 2024-11-21 | -2.1% | legal | SEC EDGAR | MGNX 8-K: 5.02 (SEC Filing) |
| 2026-02-23 | +2.1% | news | GlobeNewswire | MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial - GlobeNewswire |
| 2025-03-19 | +1.6% | earnings | Seeking Alpha | MacroGenics FY 2024 Earnings Preview |
| 2025-02-27 | -1.1% | news | Seeking Alpha | MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far |
| 2026-04-17 | +1.0% | legal | Insider Monkey | B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity |
| 2026-04-17 | +1.0% | legal | Yahoo Finance | B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity - Yahoo Finance |
| 2025-11-20 | -0.9% | legal | SEC EDGAR | MGNX 8-K: 5.02 (SEC Filing) |
| 2022-12-21 | +0.8% | legal | SEC EDGAR | MGNX 8-K: 5.02 (SEC Filing) |
| 2026-04-08 | -0.5% | legal | MT Newswires | MacroGenics Says US FDA Lifts Partial Clinical Hold on Lorigerlimab Trial |
| 2026-04-08 | -0.5% | legal | GlobeNewswire | FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study |
| 2026-04-08 | -0.5% | news | Simply Wall St. | April 2026's Most Promising Penny Stocks |
| 2026-04-08 | -0.5% | legal | SEC EDGAR | MGNX 8-K: 8.01 (SEC Filing) |
| 2026-04-08 | -0.5% | earnings | MarketBeat | MacroGenics (NASDAQ:MGNX) Stock Crosses Above Fifty Day Moving Average - What's Next? - MarketBeat |
| 2026-04-08 | -0.5% | legal | Stock Titan | MacroGenics can enroll new cancer patients after FDA lifts study hold - Stock Titan |
| 2026-04-08 | -0.5% | legal | Stock Titan | FDA lifts hold on MacroGenics (NASDAQ: MGNX) LINNET gynecologic cancer trial - Stock Titan |
| 2026-04-08 | -0.5% | legal | GlobeNewswire | FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study - GlobeNewswire |
| 2023-05-09 | -0.4% | legal | SEC EDGAR | MGNX 8-K: 2.02 and (SEC Filing) |
| 2024-12-05 | +0.3% | news | Seeking Alpha | MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy |
| 2025-07-11 | +0.2% | news | Yahoo Finance | MacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the company - Yahoo Finance |
| 2026-04-10 | -0.0% | analyst | MT Newswires | B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3 |
| 2026-04-10 | -0.0% | news | Seeking Alpha | MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble |
| 2026-04-10 | -0.0% | earnings | MarketBeat | JPMorgan Chase & Co. Increases Stake in MacroGenics, Inc. $MGNX - MarketBeat |
| 2026-04-10 | -0.0% | news | Seeking Alpha | MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble (MGNX) - Seeking Alpha |
| 2026-04-10 | -0.0% | news | Xã Vĩnh Công | What support levels matter for MacroGenics (MGNX) Stock | Price at $3.70, Up 7.56% - Investment Signal Network - Xã Vĩnh Công |
| 2023-03-09 | -0.0% | legal | SEC EDGAR | MGNX 8-K: 1.01, 8.01 (SEC Filing) |